Britannia Pharmaceuticals’ apomorphine shows promise in Phase 3 TOLEDO trial for Parkinson’s disease
Britannia Pharmaceuticals, a subsidiary of the British pharma group, has announced successful Phase 3 results for its APO-go/MOVAPO (apomorphine) subcutaneous infusion, marking a significant advancement in the treatment of Parkinson’s disease. The TOLEDO trial demonstrated that apomorphine infusion effectively relieves persistent motor fluctuations in patients whose symptoms are not adequately controlled by oral medications. The […]